AREG and graft versus host disease: Adoptive cell transfer (ACT) of IL-33 activated T9 cells (T9IL-33) decreased GVHD severity and increased GVT activity via two distinct mechanisms: decrease of fatal immunity by amphiregulin expression and increase of antileukemic activity via CD8α expression (23).